7 September 2020

Back British biotech by improving the clinical trials process

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.

The UK has a thriving life sciences sector. With three of the world’s top ten universities in the field – Oxford, Cambridge and UCL – plus prominent bioscience clusters in other British university cities such as Nottingham and Cardiff, UK research accounts for 12% of all life sciences academic citations worldwide (and nearly a fifth of the top 1% of these).

To read the full article, please click here.

Recent Articles

16 October 2020

Winter nerves in boardrooms could trigger second round of fundraisings

LGB & Co. CEO Andrew Boyle contributed to an article in The Times on the possibility of a new round of fundraising for UK-listed companies.

Read more

News & Insights

14 October 2020

Should Companies Turn to Debt or Equity Financing to Navigate the Crisis?

Andrew Boyle, CEO of LGB & Co. Read more

News & Insights

12 October 2020

Scancell announces a further £30m investment by funds managed by Redmile, LLC

Scancell Holdings plc, one of our longstanding corporate clients, has announced< Read more

Deals